Acurx Pharmaceuticals Advances Recurrent CDI Trial, Strengthens IP Portfolio

Event summary

  • Acurx received a new patent from the USPTO for DNA pol IIIC inhibitors, extending protection to December 2039.
  • Launched a Phase 2 clinical trial for ibezapolstat in recurrent CDI patients, aiming to shift treatment paradigms.
  • Raised $3.1 million through a registered direct offering and private placement in April 2026.
  • Presented preclinical data at ESCMID Global showing gut microbiome preservation with DNA pol IIIC inhibitors.
  • Ended Q1 2026 with $9.3 million in cash, up from $7.6 million at the end of 2025.

The big picture

Acurx Pharmaceuticals is positioning itself at the forefront of antibiotic innovation with its DNA pol IIIC inhibitors, particularly ibezapolstat. The company's strategic focus on recurrent CDI and its robust intellectual property portfolio could set a new benchmark in treating difficult-to-treat bacterial infections. The recent funding and preclinical data reinforce its potential to disrupt the antibiotic market, but success hinges on regulatory clarity and clinical trial outcomes.

What we're watching

Regulatory Clarity
Whether the FDA formalizes the one-trial requirement for registration, which could streamline Acurx's clinical development programs.
Trial Success
The outcome of the Phase 2 trial in recurrent CDI patients, which could position ibezapolstat as a new standard of care.
Financial Sustainability
The pace at which Acurx can secure additional funding to support its clinical trials and operational expenses.